Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesSGLT2Issue 731

AACE: Dapagliflozin Reduces Postprandial Glucose in Type 2 Diabetes

Dapagliflozin as an add-on therapy to glimepiride, pioglitazone, or sitagliptin significantly reduces postprandial plasma glucose in type 2 diabetes patients.... 

Advertisement

The US Food and Drug Administration approved dapagliflozin on January 8, 2014, for use in glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowers plasma glucose concentration by increasing renal glucose excretion, independent from insulin secretion.

The authors point out that control of fasting hyperglycemia alone may not be optimal for achieving long term glucose control, as indicated by HbA1c <7.0%, in patients with type 2 diabetes mellitus (T2DM). The current study evaluated postprandial glucose.

In three phase 3 randomized trials, type 2 diabetes patients received 10 mg/day dapagliflozin or placebo as an add-on therapy to glimepiride (n=596), pioglitazone (n=420) and sitagliptin with or without metformin (n=451).

The study showed that the addition of dapagliflozin significantly reduced postprandial plasma glucose compared with placebo: placebo-corrected mean changes from baseline at 24 weeks in 2-hour postprandial plasma glucose for dapagliflozin were -49.1 (-64.1, -34.1) mg/dL with glimepiride, -53.3 (-71.1, -35.6) mg/dL with pioglitazone, and -42.9 (-52.1, -33.8) mg/dL with sitagliptin.

According to the authors, "Observational studies suggest that postprandial glucose may be more predictive of cardiovascular morbidity and mortality and microvascular complications than fasting plasma glucose.

"Higher postprandial blood glucose concentrations may lead to increased glucose filtration, allowing for greater glucose excretion with SGLT2 inhibition and effective postprandial glucose lowering, thus potentially preventing vascular complications," the authors write.

Practice Pearls:
  • The addition of dapagliflozin significantly reduced postprandial plasma glucose compared with placebo
  • PPG may be more predictive of cardiovascular morbidity and mortality and microvascular complications than fasting plasma glucose.
  • The number of adverse events was similar for dapagliflozin and placebo.

The study was presented at the American Association of Clinical Endocrinologists annual meeting held from May 14th to 18th in Las Vegas, Nevada. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  BG ControlType 2 DiabetesSGLT2Issue 731

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Important Advances in Type 1 Diabetes Research
Posted June 25, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Would you be interested in a urine test strip product that measures microalbumin and creatinine levels to determine kidney failure risk in your patients?

CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0